Satraplatin is under clinical development by Dayton Therapeutics and currently in Phase III for T-Cell Lymphomas. According to GlobalData, Phase III drugs for T-Cell Lymphomas have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Satraplatin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Satraplatin is under development for the treatment of primary CNS lymphoma and T-cell lymphoma. The drug candidate is a fourth-generation orally bioavailable precision platinum compound. It is being developed based on Artificial Intelligence (AI) platform.
Dayton Therapeutics overview
Dayton Therapeutics (Dayton) is a clinical oncology company that develops compounds for the treatment of cancer indications with limited therapeutic options. Dayton is headquartered in Zug, Switzerland.
For a complete picture of Satraplatin’s drug-specific PTSR and LoA scores, buy the report here.